Vitamin C reduces COVID-19 risk: real-time meta analysis of 75 studies (Version 83)
, Jan 2026
Vitamin C for COVID-19
6th treatment shown to reduce risk in
September 2020, now with p = 0.00000002 from 75 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Significantly lower risk is seen for mortality, ICU admission, hospitalization, and recovery. 26 studies from 26 independent teams in 13 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 21% [15‑28%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies. Clinical outcomes suggest benefit while viral and case outcomes do not, consistent with an intervention that aids the immune system or recovery but may have limited antiviral effects. Early treatment is more effective than late treatment.
Results are robust — in exclusion sensitivity analysis 32 of 75 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
Control Vitamin C
6 RCTs with 1,420 patients have not reported results (up to 4 years late).
The European Food Safety Authority has found evidence for a causal relationship between the intake of vitamin C and optimal immune system function1,2.
Early cessation of high-dose IV treatment may result in a detrimental rebound effect3. Ongoing treatment is more effective than early cessation: 33% [22‑42%] vs. 16% [-31‑46%].
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. Dietary sources may be preferred. The quality of non-prescription supplements varies widely and the quantity of the active ingredient may be significantly lower than stated4-6. High doses may increase the risk of kidney stones7, with risk depending on formulation, predisposition, diet, and hydration8. Choi et al. show the highest bioavailability from fruit and vegetable juice. All data and sources to reproduce this analysis are in the appendix.
7 other meta analyses show significant improvements with vitamin C for mortality10-14, progression15, severity10,14, and cases16.
7 meta analyses show significant improvements with vitamin C for mortality1-5,
progression6,
severity1,5, and
cases7.
1.
Bhowmik et al., Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: A meta-analysis, Health Science Reports, doi:10.1002/hsr2.762.
2.
Olczak-Pruc et al., Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis, Nutrients, doi:10.3390/nu14194217.
3.
Kow et al., The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, Inflammopharmacology, doi:10.1007/s10787-023-01200-5.
4.
Kow (B) et al., Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, International Journal of Pharmacy Practice, doi:10.1093/ijpp/riae003.
5.
Qin et al., Effects of Vitamin C Supplements on Clinical Outcomes and Hospitalization Duration for Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis, Nutrition Reviews, doi:10.1093/nutrit/nuae154.
Covid Analysis et al., Jan 2026, preprint, 1 author.
